Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2012-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are more likely to have recurring symptoms. Using a novel "clotting chamber" the investigators have shown that patients with diabetes are more likely to develop blood clots. This study will look at the role of different blood thinning medications in patients with diabetes. If successful, the investigators will provide evidence to conduct large clinical studies to look at the role of additional blood thinning medication in reducing heart attacks and strokes in patients with diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Athero-Protective Effects of Clopidogrel

NCT01283282

Coronary Artery Disease

COMPLETED PHASE4

Platelets Induced Vasodilation, in Vitro and in Vivo Study

NCT00152646

Peripheral Arterial Disease

UNKNOWN PHASE4

The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

NCT00644657

Coronary Artery Disease Chest Pain

COMPLETED NA

Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents

NCT00947843

Coronary Heart Disease

COMPLETED PHASE4

A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers

NCT01603342

Haemostasis Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to compare the effect of Clopidogrel on platelet dependent thrombosis in patients with T2DM and CAD with placebo. The Badimon chamber, an ex vivo arterial injury model is used for this purpose. This model simulates the in vivo situation of high shear arterial wall damage and helps to quantify thrombus which is the sum endpoint of all haemostatic abnormalities seen in vitro.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

C

Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).

Group Type ACTIVE_COMPARATOR

clopidogrel

Intervention Type DRUG

75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.

P

Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

clopidogrel

75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.

Intervention Type DRUG

placebo

Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plavix, 75 milligrams Sanofi Pharma Bristol-Myers Squibb SNC 174 Avenue de France F-75013 Paris - France EU/1/98/069/005a

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with T2DM and CAS as defined below:

* Clinical definitions
* T2DM: Diagnosed according to the WHO criteria \[53\].
* CAD:Presence of any one of the following: Angina plus positive exercise tolerance test, enzyme and/or Q wave positive myocardial infarction, angiographic evidence ( \>50% stenosis of one vessel), percutaneous or surgical coronary revascularisation.
* Aged between 18 and 75
* Provided written consent for participation in the trial prior to any study-specific procedures or requirements.

Exclusion Criteria

* Contraindication to Clopidogrel
* Smoking (current smokers and patients who quit smoking less than six months)
* Malignancy(diagnosed or under investigation)
* Haematological disorders (Anaemia, malignancy, bleeding disorders)
* Women of child-bearing potential
* Use of corticosteroids/other antithrombotic agents(warfarin)
* Chronic liver disease (Cirrhosis, malignancy and patients with more than twice the upper limit of liver function tests)
* Unable to consent.
* Use of other investigational study drugs within 1 year prior to study entry
* Previous participation in this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No